Study of a Polymorphism in Patients With Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00900185|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : April 30, 2015
RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA.
PURPOSE: This laboratory study is looking at blood samples from patients with prostate cancer and from healthy participants to identify a polymorphism that may help in the study of prostate cancer.
|Condition or disease||Intervention/treatment|
|Prostate Cancer||Genetic: mutation analysis Genetic: polymerase chain reaction Genetic: polymorphism analysis|
- Determine the incidence of the D104N COL18A1 polymorphism in patients with prostate cancer.
- Determine the incidence of this polymorphism in African-American patients with prostate cancer.
OUTLINE: This is a retrospective, multicenter study.
DNA is extracted from preexisting serum samples and polymerase chain reaction is performed to determine the genotype pattern.
PROJECTED ACCRUAL: A total of 500 patients and 250 healthy participants will be accrued for this study.
|Study Type :||Observational|
|Estimated Enrollment :||750 participants|
|Official Title:||Retrospective Analysis of Endostatin Genotype in Prostate Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (D104N) in Endostatin and Prostate Cancer|
- Frequency of D104N COL18A1 polymorphism in patients with prostate cancer and in healthy participants
- Frequency of D104N COL18A1 polymorphism in African-American patients with prostate cancer and in healthy participants
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900185
|Study Chair:||William D. Figg, PharmD||National Cancer Institute (NCI)|